

1Q 2024 Revenue

April 25, 2024

2024



Disclaimer

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on expectations and assumptions that we believe to be reasonable when made, but that may not prove to be accurate. By their nature, forward-looking statements involve risk and uncertainty. Consequently, the company cannot guarantee their accuracy and their completeness, and actual results may differ materially from those the company anticipated due to a number of uncertainties, many of which the company is not aware of.

For additional information concerning important factors that may cause the company's actual results to differ materially from expectations and underlying assumptions, please refer to the reports filed by the company with the Autorité des Marchés Financiers.

Any forward-looking statement speaks only as of the date on which it is made, and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Cette présentation contient des "déclarations prospectives" au sens de la loi « Private Securities Litigation Reform Act » de 1995. Les déclarations prospectives sont fondées sur des attentes et des hypothèses que nous estimons raisonnables au moment où elles sont formulées, mais qui peuvent s'avérer inexactes. De par leur nature, les déclarations prospectives impliquent des risques et des incertitudes. Par conséquent, l'entreprise ne peut garantir leur exactitude et leur exhaustivité, et les résultats réels peuvent différer matériellement de ceux anticipés par l'entreprise en raison d'un certain nombre d'incertitudes, dont la plupart ne sont pas connues de l'entreprise.

Pour plus d'informations sur les facteurs importants susceptibles d'entraîner une différence significative entre les résultats réels de la société et les attentes et hypothèses sous-jacentes, veuillez-vous référer aux rapports déposés par la société auprès de l'Autorité des Marchés Financiers.

Toute déclaration prospective n'est valable qu'à la date à laquelle elle est faite, et nous n'assumons aucune obligation de mettre à jour ou de réviser une déclaration prospective, que ce soit à la suite de nouvelles informations, d'événements futurs ou pour toute autre raison, sauf si la loi l'exige.



The 1Q 2024 Big picture

Revenue
1Q 2024
€155.9m

+6.9%
reported


+6.0%
LFL

Revenue

- Solid growth in the first quarter
- Main contributors : digitization solutions, marketing and international operations




1Q 2024 Revenue up 6.0% L.f.I





1Q 2024 Revenue growth by division






Software & Services

48%
Of 1Q Group revenue

€74.3m
Revenue

-0.1%
-€0.1m



In million €

Total Software & services

Cegedim Santé

Insurance, HR,
Pharmacies, and
other services

International
businesses

	Revenue		Change 2024 / 2023		
	1Q 2023	1Q 2024	€ m	% Reported	% L.f.l.
Total Software & services	74.4	74.3	-0.1	-0.1 %	-1.7%
Cegedim Santé	20.6	18.0	-2.6	-12.6%	-17.1%
Insurance, HR, Pharmacies, and other services	41.3	42.7	+1.4	+3.6%	+3.5%
International businesses	12.5	13.6	+1.1	+8.7%	+6.6%

Comments

- Cegedim Santé revenue down 17.1% lfl mainly due to « Ségur de la Santé » and some revenue postponed to Q2 2024. Positive scope effect due to the integration of Visiodent's revenues since March 1st.
- Other French activities grew by 3.6% thanks to HR activities and Insurance.
- International businesses strong growth mainly in UK Pharmacies (Pharmacy First program) and Spanish hospitals.




Flow

16%
Of 1Q Group revenue

€25.3m
Revenue

+5.5%
+€1.3m



In million €	Revenue		Change 2024 / 2023		
	1Q 2023	1Q 2024	€ m	% Reported	% L.f.l.
Total Flow	24.0	25.3	+1.3	+5.5%	+5.3%
e-business	14.2	15.4	+1.2	+8.9%	+8.6%
Third-party payment	9.8	9.9	+0.1	+0.5%	+0.5%

Comments

- E-business flows grew by 8.9%. Both Invoices digitalization and Health flows practices contributed to the growth.
- Third-party payer systems in France experienced growth thanks to volumes and detection of fraud solution (facial stability due to business with Allianz relocated in BPO).




Data & Marketing

17%
Of 1Q Group revenue

€27.0m
Revenue

+9.8%
+€2.4m



In million €

Total Data & Marketing

Data

Marketing

	Revenue		Change 2024 / 2023		
	1Q 2023	1Q 2024	€ m	% Reported	% L.f.l.
Total Data & Marketing	24.6	27.0	+2.4	+9.8%	+9.8%
Data	13.1	13.0	-0.1	-0.6%	-0.6%
Marketing	11.5	14.0	+2.5	+21.7%	+21.7%

Comments

- Stable activity in Data with French sales more dynamic than international scope.
- Positive trend in Advertising in pharmacies with additional special campaigns.




BPO

13%
Of 1Q Group revenue

€20.2m
Revenue

+39.7%
+€5.8m



In million €	Revenue		Change 2024 / 2023		
	1Q 2023	1Q 2024	€ m	% Reported	% L.f.l.
Total BPO	14.4	20.2	+5.8	+39.7%	+39.7%
Insurance BPO	8.8	14.5	+5.7	+65.2%	+65.2%
Business Services* BPO	5.6	5.7	+0.1	+0.3%	+0.3%

* BPO of HR and digitization activities

Comments

- BPO operations continued to post double-digit growth over the first quarter driven by Insurance activity which benefited from comparison effect due to the start of the Allianz contract in 2Q 2023 as well as good momentum for its overflow solution.




Outlook

Outlook 2024



2024 Revenue

Growth
range 5 to 8%
like for like



Recurring operating
income

Increasing

*Disclosure: Based on currently available information.
The Group does not provide earnings estimates or forecasts.*



2024 – Financial agenda

June 14

Shareholders'
meeting

2024

July 25

After the market closes

Revenue
1st semester

2024

September 26

After the market closes

Earnings
1st semester


2024

October 24

After the market closes

Revenue
3rd quarter

2024



Thank you for your attention

For any additional information
Investor.relations@cegedim.com

www.cegedim.fr/finance



Société anonyme au capital de 13 336 506,43€ | 137 rue d'Aguesseau 92100 Boulogne-Billancourt